RxDoctor Payments Data

Joseph Coladonato, MD

Nephrology · Greensboro, NCNPI 1073557633

Payments from drug & device makers

$21,322in general payments, 2019–2025

Across 331 payments — averaging $64.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Enterprises LLC$10K
  • Mallinckrodt Hospital Products Inc.$6K
  • Amgen$1K
  • AstraZeneca$784
  • Otsuka America Pharmaceutical, Inc.$478
  • Bayer$439
  • plus $3K from 22 others

What the payments were for

  • Speaking & faculty fees$14,60068%
  • Travel & lodging$1281%
  • Food & beverage$6,10429%
  • Education$4902%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,322 in reported general payments places this provider in the 80th percentile of 366 nephrology providers in North Carolina.

See all nephrology providers in North Carolina

Medicare billing

Part B allowed, 2024
$148,600
Medicare patients
282
Services billed
894

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide48$120,622
AuryxiaFerric Citrate43$99,007
Lanthanum Carbonate16$34,636
FarxigaDapagliflozin Propanediol37$22,307
OzempicSemaglutide12$11,198
Sevelamer Carbonate60$10,922
VeltassaPatiromer Calcium Sorbitex13$10,836
KerendiaFinerenone13$8,614
Calcium Acetate26$2,129
Hydralazine Hcl81$1,501
Calcitriol70$1,389
Mycophenolate Mofetil30$1,304
Amlodipine Besylate175$1,211
Metoprolol Succinate94$1,132
Dapsone19$953

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$161$120,62248 claims
Akebia Therapeutics IncAuryxia$118$99,00743 claims
AstraZenecaFarxiga$784$22,30737 claims
Novo NordiskOzempic$65$11,19812 claims
BayerKerendia$439$8,61413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 366 nephrology providers in North Carolina.

Other nephrology in Greensboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →